Currently, cancer immunotherapy is one of the most popular research areas in cancer treatment research. Cancer immunotherapy(also called immuno-oncology) refers to a new type of treatment that stimulates the activities of the immune system to specifically remove tumor cells. Immunotherapy has the advantages of high specificity, lasting impact, few side effects, etc. Previously, Science Magazine called 2013 a "turning point in cancer" as cancer immunotherapy, which had been in the works for decades, had finally proven its potential and emerged in the top spot amongst the top ten scientific breakthroughs in 2013. In recent years, cancer immunotherapy has displayed remarkable clinical results, especially in adoptive cell therapies (such as CAR-T, CAR-NK etc.) and immune checkpoint inhibitors (such as PD-1, CTLA-4 antibody).
Shanghai Model Organisms strives to provide more valuable animal models for the development of immunotherapy and antibody therapeutics, and to aid the research and development of immunologic drugs for cancer treatment.
Repository for Immune-HU models
As of 2014, Shanghai Model Organisms has independently developed more than 60 humanized immune checkpoint mouse models (Immune-Hu models), where only the humanized immune checkpoint protein is expressed in mice by replacing the corresponding murine gene with the human gene. Our models have been verified in collaboration with several renowned pharmaceutical companies to be ideal for evaluating the efficacy of anti-tumor antibody therapeutics.
We are currently working on more targeted humanized mice and we look forward to sharing the news in the future.